A Research Study to Compare Blood Levels of Two Different Versions of Cagrilintide in Adults With Excess Body Weight

NCT07605052 · Not yet recruiting

Last updated 2026-05-28

This study compares how two different versions of the drug cagrilintide are absorbed into the bloodstream in adults who are overweight or have obesity.

Status Not yet recruiting Approved but enrollment has not started.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 50 people Planned (estimated).

Who can join Ages 18–64 · all sexes

Timeline Started 2026-05 · est. completion 2026-09

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT07605052 ↗

Description as written by the study sponsor.

The purpose of this clinical study is to compare 2 different versions cagrilintide and see how these work in people living with excess body weight. Participant will get either cagrilintide B or cagrilintide D injections. Which treatment participant will get is decided by chance. Participant will be in this clinical study for about 14 weeks.

Treatments tested

Cagrilintide B Drug

Cagrilintide B will be administered subcutaneously.
Cagrilintide D Drug

Cagrilintide D will be administered subcutaneously.

Main thing measured	AUCss: area under the total cagrilintide concentration-time curve at steady state after 5th dosing of cagrilintide
Sponsor	Novo Nordisk A/S
Conditions studied	Overweight, Obesity
GLP-1 drugs	cagrilintide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07605052 ↗